CSIMarket Company Name, Ticker, Industry, else..
 
  (ICCC)
Other Ticker:  
 
 
Price: $3.7100 $0.13 3.631%
Day's High: $3.74 Week Perf: -2.11 %
Day's Low: $ 3.34 30 Day Perf: 1.09 %
Volume (M): 106 52 Wk High: $ 5.64
Volume (M$): $ 392 52 Wk Avg: $4.73
Open: $3.59 52 Wk Low: $3.34



 Market Capitalization (Millions $) 29
 Shares Outstanding (Millions) 8
 Employees -
 Revenues (TTM) (Millions $) 20
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 1


Immucell Corp is a biotechnology company that focuses on developing and producing innovative solutions for animal health. The company specializes in the production of veterinary vaccines and other immune-stimulating products. Immucell's goal is to improve the health and productivity of animals by providing effective and safe immunological solutions. They have a range of products for various species such as cattle, poultry, and swine. Immucell Corp is committed to research and development, ensuring the continuous advancement of their products and contributing to the welfare of animals worldwide.


   Company Address: 56 Evergreen Drive Portland 4103 ME
   Company Phone Number: 878-2770   Stock Exchange / Ticker: NASDAQ ICCC


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

ImmuCells Regulatory Progress on Re-Tain: A Game Changer for Dairy and Beef Cattle Health

Published Wed, Jun 5 2024 8:05 PM UTC

'PORTLAND, Maine, June 05, 2024 - ImmuCell Corporation (Nasdaq: ICCC), a burgeoning animal health company, is making waves with its latest regulatory update on its product development initiative for Re-Tain. Here are the key points you need to know about this potentially transformative development.''Re-Tain: A Quick Overview'Re-Tain is a promising product developed by ImmuCe...
Immucell Corp

ICCC Records Impressive Surge of 9.818% in Revenue during Fiscal Q3 of 2023

Immucell Corp (ICCC) recently reported its fiscal third quarter results for 2023, and the numbers indicate a promising outlook for the company. While the loss per share increased slightly year on year, there are several key factors that paint a bullish picture for Immucell Corp.
Firstly, despite the increase in loss per share, the company experienced a significant improvement in revenue, with a 9.818% increase to $5.27 million compared to the same period last year. This growth is impressive and suggests that Immucell Corp's products and services are in demand.
Immucell Corp

Immucell Corp Faces Challenging Times as Revenue Plunges by Record-Breaking -21.171% in Q2 of 2023

Immucell Corp, a company specializing in the development and production of innovative animal health products, has recently reported an increase in losses for the period from April to June 30, 2023. The company's net loss per share rose to $0.18 from $0.09, while its revenue fell by 21.171% to $3.04 million from $3.86 million in the previous year.
This decline in revenue is significant when compared to the average performance of the In Vitro & In Vivo Diagnostic Substances industry, which saw a top-line rise during the same period. It indicates that Immucell Corp is struggling to keep up with its competitors in terms of generating revenue.
Immucell Corp

Immucell Corp Struggles as Deficit Expands to $-0.30 and Revenue Plummets in First Quarter of 2023 Earnings Season

The first quarter of 2023 was a challenging one for Immucell Corp, as the company posted a deficit per stock of $-0.30 per share, compared to $0.07 a year prior. This translates to a dramatic decrease for shareholders of the company. Furthermore, the deficit grew from $-0.22 per share from the prior quarter, indicating ongoing struggles for the company.
Revenue for Immucell Corp also took a hit during the first quarter of 2023, fading by -42.555% to $3.45 million from $6.00 million in the same quarter a year prior. Sequentially, revenue deteriorated by -11.873% from $3.91 million. This is a significant decrease in revenue and should set alarm bells ringing within the company.
Immucell Corp logged a net deficit of $-2.315 million for the first quarter of 2023, instead of 0 in the same quarter a year before. This highlights the financial challenges the company is currently facing.
The company must strategize and take measures to prevent a further deterioration of its financial situation. Shareholders will want to see a plan of action going forward from Immucell Corp.






's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com